Atherosclerosis News

Abbott and AstraZeneca announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR , a medication used along with diet to reduce high cholesterol.

Ligand Pharmaceuticals KineMed, Inc., announced today the appointment of Robert Stein, MD, PhD, as Chief Executive Officer of the Company, effective August 1, 2008, and Member of its Board of Directors.

Wyeth today extended a partnership with drug developer Karo Bio of Sweden, through which the companies collaborate to develop drugs to treat the artery disease atherosclerosis.

As body mass index increases, the likelihood that atherosclerosis will progress after coronary artery bypass grafting also rises, US researchers report.

"...low cholesterol levels, even though they are in a proper proportion of HDL and LDL can be deadly." The "cholesterol is harmful" hypothesis is but one of several theories that have been advanced over the ...

More than 106 million Americans have high cholesterol, according to the American Heart Association.

To the Editor: In the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression study by Kastelein et al.

Robert Temple, M.D., is Director of the Office of Medical Policy in the Food and Drug Administration's Center for Drug Evaluation and Research.

We've been following the Vytorin controversy for some time now, with studies questioning the effects of Vytorin - and cholesterol in general - when it comes to atherosclerosis and heart disease.

Robert Temple, M.D., is Director of the Office of Medical Policy in the Food and Drug Administration's Center for Drug Evaluation and Research.

A Ministry of Health drug price inspection, aiming to clarify the causes of price increases, at a Hanoi drug store last year The price of several types of medicine have allegedly increased much more than local ...

RDATE:17072008 Dublin - Research and Markets has announced the addition of the "Dyslipidemia: Opportunities in Cardiovascular Risk Reduction" report to their offering.

Recent recommendations to give cholesterol drugs to children as young as 8 years old have sparked a lot of reaction from parents and doctors.

Does a failed trial of Pfizer 's cholesterol-lowering pill Lipitor make the rival drug Vytorin look better by comparison? No, say several top cardiologists.

Supplements of the lycopene, the carotenoid that give tomatoes their red colour, may be as effective as statins to reduce the formation of plaques in the arteries that cause atherosclerosis, says a new study ...

Flurizan aimed to stop development of all amyloid plaques. Gamma-secretase modulators GSMs only go after the long ones.

Controversies surrounding fixed-dose combination statins have drawn attention to Vytorin as well as issues in drug development and approval.

From the Metabolic Research Centre , School of Medicine and Pharmacology, University of Western Australia, Perth; and Bristol-Myers Squibb R&D , Princeton, NJ.

Arteriosclerosis, Thrombosis, and Vascular Biology. 2008 Published online before print June 19, 2008, doi: 10.1161/ATVBAHA.108.164541 Submitted on February 7, 2008 Accepted on June 5, 2008 Extended-Release ...

A genetic quirk in the production of one protein helps explain why some people don't get the full cholesterol-lowering benefit of statin drugs, researchers report.